Healthy Clinical Trial
Official title:
Test-retest Reliability of Lung Diffusing Capacity for Nitric Oxide During Light and Moderate Intensity Cycling Exercise
NCT number | NCT04618302 |
Other study ID # | 2020-01756 |
Secondary ID | |
Status | Completed |
Phase | |
First received | |
Last updated | |
Start date | October 19, 2020 |
Est. completion date | January 1, 2021 |
Verified date | April 2021 |
Source | University of Zurich |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
This study investigates the test-retest reliability of the lung diffusing capacity for nitric oxide in healthy individuals during exercise.
Status | Completed |
Enrollment | 17 |
Est. completion date | January 1, 2021 |
Est. primary completion date | December 31, 2020 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Healthy - Age 18 yrs and older - Ability to follow study procedures and instructions in German Exclusion Criteria: - Any known cardiopulmonary or metabolic diseases (e.g., heart disease, diabetes mellitus etc) - Obesity (BMI > 30kg/m2) - Smoking (ex-smoker allowed; if they stopped smoking at least one year before the examination) - Mental impairment leading to inability to cooperate - Respiratory infection in the last two weeks - Forced expiratory volume in 1s/ forced vital capacity (FEV1/FVC ratio) FEV1/FVC ratio < lower limit of normal according to equations by Quanjer et al. Eur Respir J 2012. |
Country | Name | City | State |
---|---|---|---|
Switzerland | University of Zurich and University Hospital of Zurich | Zurich |
Lead Sponsor | Collaborator |
---|---|
Thomas Radtke |
Switzerland,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Diffusing capacity for nitric oxide (DLNO) | DLNO (in ml/min/mmHg) measured at 80% of the gas exchange threshold during cycling exercise. | At second study visit | |
Primary | Diffusing capacity for nitric oxide (DLNO) | DLNO (in ml/min/mmHg) measured at 80% of the gas exchange threshold during cycling exercise. | At third study visit, approximately 1-2 weeks after second study visit | |
Secondary | Diffusing capacity for nitric oxide (DLNO) | DLNO (in ml/min/mmHg) measured at 50% of the gas exchange threshold during cycling exercise. | At second study visit | |
Secondary | Diffusing capacity for nitric oxide (DLNO) | DLNO (in ml/min/mmHg) measured at 50% of the gas exchange threshold during cycling exercise. | At third study visit, approximately 1-2 weeks after second study visit | |
Secondary | Diffusing capacity for carbon monoxide (DLCO) | DLCO (in ml/min/mmHg) measured at 50% of the gas exchange threshold during cycling exercise. | At second study visit | |
Secondary | Diffusing capacity for carbon monoxide (DLCO) | DLCO (in ml/min/mmHg) measured at 50% of the gas exchange threshold during cycling exercise. | At third study visit, approximately 1-2 weeks after second study visit | |
Secondary | Diffusing capacity for carbon monoxide (DLCO) | Agreement in DLCO (in ml/min/mmHg) measured at 80% of the gas exchange threshold during cycling exercise. | At second study visit | |
Secondary | Diffusing capacity for carbon monoxide (DLCO) | Agreement in DLCO (in ml/min/mmHg) measured at 80% of the gas exchange threshold during cycling exercise. | At third study visit, approximately 1-2 weeks after second study visit | |
Secondary | Alveolar volume (VA) | VA (in L) measured at 50% of the gas exchange threshold during cycling exercise. | At second study visit | |
Secondary | Alveolar volume (VA) | VA (in L) measured at 50% of the gas exchange threshold during cycling exercise. | At third study visit, approximately 1-2 weeks after second study visit | |
Secondary | Alveolar volume (VA) | Alveolar volume (in L) measured at 80% of the gas exchange threshold during cycling exercise. | At second study visit | |
Secondary | Alveolar volume (VA) | Alveolar volume (in L) measured at 80% of the gas exchange threshold during cycling exercise. | At third study visit, approximately 1-2 weeks after second study visit | |
Secondary | Breath hold time (BHT) | BHT (in s) measured at 80% of the gas exchange threshold during cycling exercise. | At second study visit | |
Secondary | Breath hold time (BHT) | BHT (in s) measured at 80% of the gas exchange threshold during cycling exercise. | At third study visit, approximately 1-2 weeks after second study visit | |
Secondary | Breath hold time (BHT) | BHT (in s) measured at 50% of the gas exchange threshold during cycling exercise. | At second study visit | |
Secondary | Breath hold time (BHT) | BHT (in s) measured at 50% of the gas exchange threshold during cycling exercise. | At third study visit, approximately 1-2 weeks after second study visit |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06052553 -
A Study of TopSpin360 Training Device
|
N/A | |
Completed |
NCT05511077 -
Biomarkers of Oat Product Intake: The BiOAT Marker Study
|
N/A | |
Recruiting |
NCT04632485 -
Early Detection of Vascular Dysfunction Using Biomarkers From Lagrangian Carotid Strain Imaging
|
||
Completed |
NCT05931237 -
Cranberry Flavan-3-ols Consumption and Gut Microbiota in Healthy Adults
|
N/A | |
Terminated |
NCT04556032 -
Effects of Ergothioneine on Cognition, Mood, and Sleep in Healthy Adult Men and Women
|
N/A | |
Completed |
NCT04527718 -
Study of the Safety, Tolerability and Pharmacokinetics of 611 in Adult Healthy Volunteers
|
Phase 1 | |
Completed |
NCT04998695 -
Health Effects of Consuming Olive Pomace Oil
|
N/A | |
Completed |
NCT04107441 -
AX-8 Drug Safety, Tolerability and Plasma Levels in Healthy Subjects
|
Phase 1 | |
Completed |
NCT04065295 -
A Study to Test How Well Healthy Men Tolerate Different Doses of BI 1356225
|
Phase 1 | |
Completed |
NCT01442831 -
Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C] TR 701 In Healthy Adult Male Subjects
|
Phase 1 | |
Terminated |
NCT05934942 -
A Study in Healthy Women to Test Whether BI 1358894 Influences the Amount of a Contraceptive in the Blood
|
Phase 1 | |
Recruiting |
NCT05525845 -
Studying the Hedonic and Homeostatic Regulation of Food Intake Using Functional MRI
|
N/A | |
Completed |
NCT05515328 -
A Study in Healthy Men to Test How BI 685509 is Processed in the Body
|
Phase 1 | |
Completed |
NCT05030857 -
Drug-drug Interaction and Food-effect Study With GLPG4716 and Midazolam in Healthy Subjects
|
Phase 1 | |
Completed |
NCT04967157 -
Cognitive Effects of Citicoline on Attention in Healthy Men and Women
|
N/A | |
Recruiting |
NCT04494269 -
A Study to Evaluate Pharmacokinetics and Safety of Tegoprazan in Subjects With Hepatic Impairment and Healthy Controls
|
Phase 1 | |
Recruiting |
NCT04714294 -
Evaluate the Safety, Tolerability and Pharmacokinetics Characteristics of HPP737 in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT04539756 -
Writing Activities and Emotions
|
N/A | |
Recruiting |
NCT04098510 -
Concentration of MitoQ in Human Skeletal Muscle
|
N/A | |
Completed |
NCT03308110 -
Bioavailability and Food Effect Study of Two Formulations of PF-06650833
|
Phase 1 |